1. Medtech Insight
  2. >>Business

Cardio Catch-Up: Trial Of Abbott’s Volt PFA Begins; IDE Study To Start This Year

 
• By Reed Miller

Abbott is behind rivals Boston Scientific and Medtronic in the race to capture share of the emerging pulsed field ablation market. PFA is set to eventually become the most common cardiac ablation modality because it is safer than radiofrequency or cryoablation.

Abbott Volt PFA
Abbott Volt PFA • Source: Abbott

The first 30 atrial fibrillation ablation procedures with Abbott’s Volt PFA (pulsed field ablation) system have been completed in Australia and Europe as part of a clinical trial to support a CE mark.

The company expects the US Food and Drug Administration to approve its plan for a US clinical trial of Volt...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, home of Medtech Insight, to focus on AI, business harmonization and long-term growth.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.